Published 3 days ago • loading... • Updated 1 day ago

Roche signs biggest-ever obesity drug deal

Harbour BioMed announced the launch of Élanç Therapeutics on March 12, 2025, to develop innovative obesity therapies.
Élanç Therapeutics aims to improve obesity treatment by increasing body weight loss while preserving muscle mass, using bispecific antibody technology.
Obesity, affecting nearly one billion people, poses serious health issues, highlighting the need for better treatment options.
Jingsong Wang stated that their bispecific antibody programs could redefine obesity therapeutics by targeting multiple pathways.

Insights by Ground AI

Does this summary seem wrong?

60 Articles

All

Left

Center

Right

Quartz

Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today

Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.Read more...

1 day ago·United States

Read Full Article

CBC News

Dad of 7-year-old with rare condition 'very scared' as Ontario family can't afford $300K annual treatment

Cena Hermus, 7, was two years old when she was diagnosed with a rare, life-threatening disorder that causes severe obesity. The medication she needs costs around $300,000 annually, something family members, who now live in Hamilton, say they can't afford.

1 day ago·Canada

Read Full Article

Investor's Business Daily

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion

Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class. The post Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion appeared first on Investor's Business Daily.

2 days ago

Read Full Article

News Medical

Waist-to-height ratio more accurate than BMI for detecting childhood obesity

Body mass index (BMI) was almost three times more likely to classify children as overweight than waist circumference-to-height ratio, according to a new study.

2 days ago·United States

Read Full Article

SWI swissinfo.ch

Swiss pharma giant Roche partners with Zealand Pharma on new obesity treatment

Roche announced that it has struck an exclusive deal with Denmark's Zealand Pharma to develop and market petrelintide, a new treatment for obesity.

2 days ago·Bern, Switzerland

Read Full Article

Fortune

Roche, Zealand Pharma in $5.3 billion pact for obesity drugs

Roche Holding licensed a new weight-loss drug from Zealand Pharma, bolstering the drugmaker’s effort to get into a hot market dominated by Novo Nordisk and Eli Lilly & Co.

2 days ago·New York, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year